Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
NNMT Inhibition, NAD+ & Obesity/Type 2 Diabetes Pathway Review (PMC, 2021) 5-Amino-1MQ as a Validated Research Tool for NNMT-Linked Metabolic Pathways A comprehensive review of NNMTs roles in obesity and type 2 diabetes published in BioMed Research International and indexed on PubMed Central evaluated 5-Amino-1MQ alongside other NNMT inhibitors
What they found: Mean weight loss: 2.6 kg vs 2.3 kg placebo , a difference of only 0.3 kg (1 %) Statistically non-significant Clinically unsatisfactory for the obesity indication Safety profile remained favorable Why it matters: The study stopped the development of AOD-9604 as a drug
Research documents its influence on ERK1/2 signaling cascades that regulate cell proliferation and migration[3][4]
Newtropin bridges this gap for healthcare professionals
2) Treatment with AOD9604 has been found to increase expression of beta-3-AR RNA, indicating that the compound has the potential to enhance lipolytic sensitivity
US$ 21.65
US$ 26.11
US$ 26.85
